The Form 4 filing, an SEC report of insider stock activity, was filed on Nov. 6, 2026. It reports a sale made on Nov. 4, two days before the filing.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-04 |
| Date of Latest Transaction | 2026-11-04 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 23,376 |
| Price | $99.15 |
| Total Transaction Value | $2,317,681.31 |
| Insider | |
| Ticker Symbol | CL |
| Company | COLGATE PALMOLIVE CO |
| Insider Name | Hazlin John |
| Insider Title | Chief Growth Officer |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 27,021 |
| Position Size Change | 46.38% |
| Filing | |
| Filing Date | 2026-11-06 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of CL shares, reported under transaction code S. The transaction information also suggests a link to an exercise or conversion, which can turn stock rights into shares.
What was the average price of the transaction?
The average sale price was $99.1479 per share, shown as $99.15 after rounding to cents.
How did this transaction affect the insider's holdings?
John Hazlin sold 23,376 shares and reported 27,021 shares owned afterward. The sale represented 46.38% of his reported shares held before the sale.
What's the total transaction value?
The sale's total value was $2,317,681.31, rounded to cents. That amount covers the one reported sale transaction.
Are there any special circumstances around this transaction?
The sale appears linked to an exercise or conversion. This link is based on a match with a code M entry for the same number of shares in the same filing. Code M covers shares received by using or converting a stock right.
Details of the related entry and the filing footnotes are unavailable. Its date, share type and account therefore cannot be checked. The share-count match alone does not confirm that the shares received were the ones sold. It also does not establish a same-day sale or explain how the exercise was paid for.
For research purposes only; not investment advice.